Cambridge Innovation Capital (CIC) invests in Forefront RF
Cambridge Innovation Capital (CIC), a leading venture capital firm embedded in the Cambridge UK ecosystem, is pleased to announce its investment in Forefront RF, with the completion of a £16 million Series A financing round.
Oxford-Cambridge region should be science ‘jewel’
Industry leaders have urged the government to make the Oxford-Cambridge region the “crown jewel” of European science and innovation.
CIC wins Best Performing Investor of the Year award by One Nucleus
For the first time, life science innovators, companies and their supporters were invited to celebrate their success in various categories, at the inaugural One Nucleus Annual Awards.
Winners
Pragmatic Semiconductor secures £182m ($231m) investment led by M&G and UK Infrastructure Bank
Largest ever European semiconductor venture funding round supports further expansion of manufacturing in the UK.
Cambridge Innovation Capital announces its investment in T-Therapeutics’ £48 Million Series A Funding
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in T-Therapeutics’ £48 Million Series A funding round alongside leading European and US life science investors Sofinnova Partners, F-Prime Capital and Digitalis Ventures, with participation from Sanofi Ventures and the University of Cambridge…
AI start-up founders reveal artificial intelligence trends for 2023
With artificial intelligence (AI) innovation surging across business, we gauge the views of AI start-up founders on the biggest trends in the space this year.
Cambridge Innovation Capital invests in Complement Therapeutics’ €72 Million Series A Funding
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in Complement Therapeutics’ €72 Million Series A funding round led by G
Cambridge Innovation Capital invests in Mosaic Therapeutics $28m Series A Funding
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life sciences businesses in the Cambridge ecosystem, has invested in Mosaic Therapeutics $28m Series A funding round.
Cambridge Innovation Capital raises £225 million ($300 million) for Fund II
Cambridge Innovation Capital (CIC), the venture capital investor focused on building world-leading deeptech and life sciences businesses connected with the Cambridge ecosystem, raises £225 million ($300 million) for its oversubscribed second fund (Fund II).
CIC participates in Microbiotica’s £50m Series B financing to advance microbiome-based therapeutics
Cambridge Innovation Capital participates in Microbiotica’s £50m Series B financing to advance microbiome-based therapeutics.Largest microbiome-related financing in Europe will advance Phase 1B clinical trials in immuno-oncology and ulcerative colitis.
Cambridge Innovation Capital looks back on 'transformational year'
Cambridge Innovation Capital presents a video which summarises some of its achievements in 2021, which was a "transformational year" for CIC, according to Managing Partner Andrew Williamson.
CIC participates in Pretzel Therapeutics’ financing round to develop first-in-class treatments for mitochondrial disease
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life science businesses in the Cambridge ecosystem, is pleased to announce its participation in the financing raised by Pretzel Therapeutics, to support development of novel therapeutics designed to address currently untreatable conditions.
Origami raises £20 million in Series C funding round led by Barclays
Cambridge based Origami has raised £20.5m of new funding to help drive its next phase of growth.
New Cambridge accelerator for deeptech startups launches with five machine learning investments
Deeptech Labs (DTL), a new post-seed accelerator aimed at deep technology (deeptech) start-ups, has been founded in Cambridge to bring the benefits of its innovation ecosystem to post-Seed deeptech companies from the UK and Europe.
Sense raises $50m Series B to accelerate launch of COVID-19 molecular test
Sense Biodetection (Sense), has announced that it has raised a $50m Series B investment to advance commercialisation of its Veros™ COVID-19 product and continue development of a portfolio of instrument-free, rapid molecular tests that enable improved access, outcomes, and value through patient-focused decentralised healthcare.
CIC participates in Gyroscope Therapeutics’ £107.8 million Series C financing
Cambridge Innovation Capital (CIC), the venture capital investor focused on deeptech and life science businesses in the Cambridge ecosystem, is pleased to announce its participation in the £107.8 million ($148 million) Series C financing raised by Gyroscope Therapeutics Limited, a clinical-stage gene therapy company focused on treating diseases of the eye.
How to collaborate with Alibaba: IP, legislation and boosting market penetration
A webinar next month is aimed at small-medium sized enterprises that intend to partner with the BATs (Baidu, Alibaba, and Tencent) or to operate a technology company that services the Chinese market.
Join CIC for its Deep Tech Series A office hours session
Here is a unique opportunity to get in front of one of the UK’s leading Deep Tech Series A investors and learn from them what a good Series A pitch looks like.
Cambridge Innovation Capital leads £7.1M Series A investment in Seldon
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, is pleased to announce that it has co-led a £7.1M Series A investment in Seldon, the Open Source DevOps company providing enterprises with the tools to manage, serve and optimise their Machine Learning models at scale, alongside AlbionVC…
Start Codon closes new £15 million venture fund to translate life science innovation into successful companies
Start Codon, a life science and healthcare business accelerator based in Cambridge, UK, today announced that it has closed Start Codon Fund I LP at £15 million ($20 million USD). The Fund will be used to support Start Codon’s offering to start-ups, which includes a minimum of £250K seed funding, business support services, expert guidance, and access to cutting-edge office and lab facilities.
Congenica completes $50m Series C funding round to advance clinical genomic analysis software and data platform
Congenica, the digital health company enabling rapid and accurate analysis of complex genomic data to transform people’s lives, is pleased to announce the completion of its Series C funding round, raising US$50m (£39m).
Cambridge Innovation Capital results reflect 'tremendous progress'
Cambridge Innovation Capital plc (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, today announces highlights from its annual results for the year ended 31 March 2020.
CIC portfolio company Inivata announces strategic collaboration and investment from NeoGenomics
Cambridge Innovation Capital (CIC), the venture capital investor enabling visionaries to build global, category-leading companies in the Cambridge ecosystem, is pleased to note that portfolio company Inivata, a leader in liquid biopsy, has today announced the formation of a strategic collaboration with NeoGenomics, Inc (NASDAQ: NEO), for the commercialisation of its InVisionFirst®-Lung liquid…
Exvastat receives grant to fund clinical study of existing drug in COVID-19 treatment
Exvastat (Ireland) Ltd, a privately held biopharmaceutical company backed by Cambridge Innovation Capital, announced the Innovative Medicines Initiative has awarded the company a €3.6m grant, following its call for developers to uncover a new use of the licensed drug therapy imatinib for the treatment of Acute Respiratory Distress Syndrome (ARDS) induced by COVID-19.
Inivata launches RaDaR™ for the detection of residual disease and recurrence
Inivata, a Cambridge Innovation Capital portfolio company and a leader in liquid biopsy, announces the availability of RaDaR™, an assay for the detection and monitoring of residual disease and recurrence in the plasma samples of patients previously diagnosed with cancer.